Teva Acquires NuPathe for $144M to Expand Its Portfolio

Teva Pharmaceutical Industries will acquire NuPathe Inc. for $3.65 per share in cash, or $144 million, to expand its portfolio of medicines to treat conditions affecting the central nervous system. In addition to the upfront cash payment, NuPathe shareholders will receive rights to get additional cash payments of up to $3.15 per share if specified sales of NuPathe's migraine treatment Zecuity are achieved over time, according to Teva. Read the full story

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments